| Shan M Flatt, MD | |
|
610 30th Ave W, Alexandria, MN 56308-3426 | |
| (320) 763-2540 | |
| (320) 763-5749 |
| Full Name | Shan M Flatt |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 610 30th Ave W, Alexandria, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265728026 | NPI | - | NPPES |
| 107477 | Other | MN | MEDICAL LICENSE |
| 1265728026 | Other | MN | NPI |
| 1265728026 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 107477 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Knute Nelson Home Care | Alexandria, MN | Home health agency |
| Alomere Health | Alexandria, MN | Hospital |
| Bethany On The Lake Llc | Alexandria, MN | Nursing home |
| Knute Nelson | Alexandria, MN | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Douglas County Hospital | 0648171413 | 101 |
News Archive
An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective.
CNS Response, Inc. announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEG®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.
A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
PROLOR Biotech, Inc., today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.
The rapid transmissibility of SARS-CoV-2 has posed a significant challenge to COVID-19 containment measures.
› Verified 8 days ago
| Entity Name | Douglas County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164424305 PECOS PAC ID: 0648171413 Enrollment ID: O20040115000387 |
News Archive
An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective.
CNS Response, Inc. announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEG®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.
A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
PROLOR Biotech, Inc., today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.
The rapid transmissibility of SARS-CoV-2 has posed a significant challenge to COVID-19 containment measures.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shan M Flatt, MD 610 30th Ave W, Alexandria, MN 56308-3426 Ph: (320) 763-2540 | Shan M Flatt, MD 610 30th Ave W, Alexandria, MN 56308-3426 Ph: (320) 763-2540 |
News Archive
An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective.
CNS Response, Inc. announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEG®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.
A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
PROLOR Biotech, Inc., today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.
The rapid transmissibility of SARS-CoV-2 has posed a significant challenge to COVID-19 containment measures.
› Verified 8 days ago
Dr. David John Lamusga, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5432 East Lake Carlos Drive, Alexandria, MN 56308 Phone: 320-763-5033 | |
Leanne J Anderson, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1527 Broadway St, Alexandria, MN 56308 Phone: 320-762-0399 | |
Timothy F Busian, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 610 30th Ave W, Alexandria, MN 56308 Phone: 320-763-5123 | |
Michael L Bristow, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 610 30th Ave W, Alexandria Clinic, Alexandria, MN 56308 Phone: 320-763-5123 Fax: 320-763-7883 | |
Wendy Carole Cudio Stephens, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 418 3rd Ave E, Alexandria, MN 56308 Phone: 320-762-2311 Fax: 320-762-8942 | |
Paul W Bergstrand, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 610 30th Ave W, Alexandria Clinic, Alexandria, MN 56308 Phone: 320-763-5123 Fax: 320-763-7883 | |
Sandra L Johnson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 610 30th Ave W, Alexandria Clinic, Alexandria, MN 56308 Phone: 320-763-5123 Fax: 320-763-7883 |